The WHO Is Building a Supranational Vaccine Authorization Mechanism

Key Takeaways

• WHO's Emergency Use Listing (EUL) guides vaccine approvals beyond national regulators
• Israel used EUL to fast‑track nOPV2, bypassing full licensure
• Committee secretary concealed ties to WHO and Gates Foundation during deliberations
• EUL transforms temporary emergency measure into de‑facto international regulatory framework
• Conflict‑of‑interest disclosures were omitted from official minutes, raising accountability concerns

Pulse Analysis

The World Health Organization’s Emergency Use Listing (EUL) was introduced as a stop‑gap during health crises, allowing products with limited data to be deployed when no approved alternative exists. Over the past few years, however, the EUL has been repurposed as an operational blueprint that national health ministries can adopt, effectively outsourcing part of their regulatory decision‑making to an international body. By defining timelines, milestones and risk thresholds, the EUL creates a pre‑set pathway that can accelerate market entry without the rigorous, independent assessment traditionally required by sovereign regulators.

Israel’s experience with the novel nOPV2 polio vaccine provides a concrete illustration of this shift. After the vaccine received EUL status in 2020, Israeli officials leaned on the WHO’s framework to justify rapid importation and deployment, despite the absence of full licensure from a stringent Western regulator. The internal committee’s deliberations were heavily influenced by WHO‑produced materials, and the decision to proceed was made before any comprehensive national dossier was reviewed. This approach effectively turned an emergency measure into a permanent regulatory conduit, blurring the line between advisory guidance and binding authority.

The revelations of undisclosed conflicts of interest—particularly the secret consulting relationship between the committee’s secretary and both the WHO and the Gates Foundation—underscore the governance challenges inherent in such supranational mechanisms. When key decision‑makers are financially tied to the entities promoting a product, transparency erodes, and public trust wanes. Policymakers worldwide must scrutinize the growing influence of the EUL and similar pathways, ensuring that national oversight remains robust, conflicts are fully disclosed, and emergency tools do not become unchecked channels for global health actors to shape domestic drug policy.